The safety and efficacy demonstrated by the on-going clinical trials of gene therapy for LCA associated with RPE65 deficiency have provided proof-of-principle for other forms of LCA; thereby establishing a greater need for making timely and accurate molecular diagnoses [3]–[5]. Here, RPE65 is linked to Leber congenital amaurosis.